RxDoctor Payments DataLook up a doctor →

Verna Guanzon, MD

Family Medicine · Madison Heights, VANPI 1861652331

Payments from drug & device makers

$27,327in general payments, 2019–2025

Across 1,521 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$5K
  • AstraZeneca$4K
  • AbbVie$3K
  • Johnson & Johnson$2K
  • Amgen$2K
  • Pfizer$1K
  • plus $10K from 44 others

What the payments were for

  • Food & beverage$27,272100%
  • Education$550%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,327 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$520,559
Medicare patients
660
Services billed
17,981

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide145$205,717
FarxigaDapagliflozin Propanediol129$127,675
EliquisApixaban107$113,094
JardianceEmpagliflozin87$100,465
JanuviaSitagliptin Phosphate43$67,503
RybelsusSemaglutide45$58,192
LinzessLinaclotide52$51,494
Tresiba Flextouch U-100Insulin Degludec24$30,339
XareltoRivaroxaban22$26,175
Tresiba Flextouch U-200Insulin Degludec19$20,651
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$20,437
ViberziEluxadoline12$19,321
Lantus SolostarInsulin Glargine,hum.Rec.Anlog79$19,118
QuliptaAtogepant17$18,653
MounjaroTirzepatide16$15,580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$5,279$263,909190 claims
AstraZenecaFarxiga, Symbicort$3,860$133,989142 claims
PfizerEliquis$1,329$113,094107 claims
Boehringer IngelheimJardiance, Tradjenta$1,251$111,022101 claims
AbbVieLinzess, Viberzi, Qulipta$2,835$89,46881 claims
MerckJanuvia$214$67,50343 claims
Johnson & JohnsonXarelto$1,991$26,17522 claims
GSKTrelegy Ellipta$462$20,43717 claims
Lilly USA, LLCMounjaro$1,063$15,58016 claims
Sumitomo Pharma America, Inc.Gemtesa$29$5,85812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Madison Heights

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →